• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by CalciMedica Inc.

    6/9/25 4:05:16 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALC alert in real time by email
    DEFA14A 1 d941163ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    CALCIMEDICA, INC.

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    SUPPLEMENT TO THE PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS

    TO BE HELD TUESDAY, JUNE 24, 2025

    This proxy statement supplement (this “Supplement”), dated June 9, 2025, supplements the proxy statement filed with the Securities and Exchange Commission (the “Commission”) on April 29, 2025 (the “Proxy Statement”) relating to the proxies being solicited by the Board of Directors (the “Board”) of CalciMedica, Inc., a Delaware corporation (the “Company” and “we” or “our”), in connection with the Company’s 2025 Annual Meeting of Stockholders to be held on Tuesday, June 24, 2025 (the “Annual Meeting”). This Supplement should be read together with the Proxy Statement. Other than as set forth below, no changes have been made to the Proxy Statement.

    The purpose of this Supplement is to provide information relating to the merger of the Company’s independent registered public accounting firm.

    On June 3, 2025, the Company was notified that Moss Adams LLP (“Moss Adams”), the Company’s independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025. The combined audit practices operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the notification of the merger, Moss Adams has resigned as the auditors of the Company and the Audit Committee of the Board approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.

    The audit report of Moss Adams on the Company’s consolidated financial statements for the year ended December 31, 2024 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.

    During the years ended December 31, 2024 and 2023, and the subsequent interim period through June 3, 2025, there were no (a) disagreements with Moss Adams on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Moss Adams’ satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its reports on the Company’s financial statements, or (b) reportable events requiring disclosure pursuant to Item 304(a)(1)(v) of Regulation S-K.

    During the years ended December 31, 2024 and 2023, and the subsequent interim period through June 3, 2025, neither the Company, nor anyone on its behalf, consulted with Baker Tilly regarding: (i) either the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements; or (ii) any matter that was either the subject of a “disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to that item, or a “reportable event,” as described in Item 304(a)(1)(v) of Regulation S-K.

    The Company provided Moss Adams with a copy of this Supplement prior to its filing with the Commission and requested that Moss Adams furnish the Company with a letter addressed to the Commission stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of Moss Adams’ letter to the Commission, dated June 6, 2025, is filed as Exhibit 16.1 to the Current Report on Form 8-K filed by the Company on June 6, 2025.

    With respect to Proposal No. 2 included in the Proxy Statement, to ratify the appointment of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025, we will consider an affirmative vote “For” Proposal No. 2 as a vote “For” ratification of Baker Tilly as the successor accounting firm following the merger and a vote “Against” Proposal No. 2 as a vote “Against” ratification of Baker Tilly as the successor accounting firm following the merger. Abstentions and broker non-votes will have no effect.

    Proxy voting instructions already returned by stockholders will remain valid and will be voted at the Annual Meeting unless revoked. Important information regarding how to vote your shares and how to change votes already cast is available in the Proxy Statement.

    Get the next $CALC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CALC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

      LA JOLLA, Calif., June 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced an upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being held June 24-26 in Vicenza, Italy. Details for the oral presentations to be presented during the sympo

      6/12/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

      Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

      5/14/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Announces Presentations at Upcoming Medical Meetings

      LA JOLLA, Calif., April 17, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation at Digestive Disease Week (DDW) 2025 being held May 3-6 in San Diego, CA, and the participation of Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, in both an oral presentation and a panel discussion at the American Society of Nephrology (ASN) 3rd Acute Kidney Injury: From Bench to Bedside Conferenc

      4/17/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF BUSINESS OFFICER Roberts Eric W bought $17,545 worth of shares (10,100 units at $1.74) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      6/9/25 4:08:15 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Bardin Stephen bought $1,690 worth of shares (1,000 units at $1.69), increasing direct ownership by 2% to 41,000 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      6/3/25 5:10:11 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Middleton Fred A bought $12,720 worth of shares (4,800 units at $2.65), increasing direct ownership by 15% to 36,514 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      12/6/24 7:12:27 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by CalciMedica Inc.

      SC 13D - CalciMedica, Inc. (0001534133) (Subject)

      11/26/24 6:03:55 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      11/14/24 3:32:39 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      11/14/24 1:05:20 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Financials

    Live finance-specific insights

    See more
    • CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

      Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose Auxora compared to placebo Clinically meaningful reduction observed for high dose Auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge Conference call and webcast to review full data set from the Ph2b CARPO trial to be held at 12 p.m. ET/ 9 a.m. PT LA JOL

      10/30/24 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

      Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT LA JOLLA, Calif., Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Prof. Robert Sutt

      10/28/24 4:05:00 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

      Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica or the Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024.

      8/12/24 4:10:00 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Leadership Updates

    Live Leadership Updates

    See more
    • CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

      Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

      5/14/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

      Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

      3/27/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

      LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D. to the Company's Board of Directors effective on January 15, 2025. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics.

      1/14/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF BUSINESS OFFICER Roberts Eric W bought $17,545 worth of shares (10,100 units at $1.74) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      6/9/25 4:08:15 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Bardin Stephen bought $1,690 worth of shares (1,000 units at $1.69), increasing direct ownership by 2% to 41,000 units (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      6/3/25 5:10:11 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Bardin Stephen

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      4/25/25 4:35:02 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    SEC Filings

    See more
    • SEC Form DEFA14A filed by CalciMedica Inc.

      DEFA14A - CalciMedica, Inc. (0001534133) (Filer)

      6/9/25 4:05:16 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by CalciMedica Inc.

      8-K - CalciMedica, Inc. (0001534133) (Filer)

      6/6/25 7:00:21 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by CalciMedica Inc.

      10-Q - CalciMedica, Inc. (0001534133) (Filer)

      5/14/25 4:15:43 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care